GGrantIndex
Sort

48,018 grants matching immunotherapy

Engineered B Cells as a Universal Platform for the Treatment of Enzymopathies

$386,667
Branden S Moriarity · University Of Minnesota · R01 · FY2021 · AI

Control of Effector and Memory T Cell Development by Inflammatory Signals

$386,661
Susan M Kaech · Yale University · R01 · FY2011 · AI

Clinical Fellowship Training Program

$386,650
Peter Pinto · Division Of Basic Sciences - Nci · ZIE · FY2013 · CA

The development of Saccharomyces (yeast) vaccines for cancer therapy

$386,587
James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Vaccine and Drug Combination Therapy for Human Cancers

$386,587
James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Sublingual Immunotherapy for Peanut Allergy

$386,575
Arvil Wesley Burks · Duke University · R01 · FY2009 · AT

A knowledge map to find Alzheimer's disease drugs

$386,555
Olivier Lichtarge · Baylor College Of Medicine · R01 · FY2020 · AG

Mechanisms of radioresistance and strategies for radiosensitization in ovarian clear cell carcinoma

$386,539
Guang Peng · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

eDyNAmiC - UCSD

$386,521
Vineet Bafna · University Of California, San Diego · OT2 · FY2025 · CA

Proj 2 - Exploiting Therapeutic Vulnerabilities

$386,498
William A Weiss · Children'S Hosp Of Philadelphia · P01 · FY2020 · CA

A HIGHLY SUPERIOR AND SELECTIVE CANCER IMMUNOTHERAPY-BASED APPROACH FOR TRIPLE-NEGATIVE BREAST CANCERS

$386,494
Rector & Visitors Of The University Of Virginia · · FY2018 · Defense Health Agency

Chemokine Modulation During SIV Infection & AIDS

$386,474
Todd A Reinhart · University Of Pittsburgh At Pittsburgh · R01 · FY2006 · AI

Inhibiting mitochondrial complex I to improve cetuximab efficacy in oral cancer

$386,463
Yong Teng · Emory University · R01 · FY2024 · DE

Project 5: Enhancement of the Anti-Tumor Activity and Targeted Applications of Third Party Donor-Derived EBV-specific T-cells

$386,442
Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2022 · CA

Amelioration of recurrent herpes keratitis

$386,437
Patrick M Stuart · Washington University · R01 · FY2007 · EY

Immune Response to Polyomavirus Infection

$386,433
Parmjeet S Randhawa · University Of Pittsburgh At Pittsburgh · R01 · FY2007 · AI

Finger Nucleases to Specifically Disrupt Coreceptor Expression

$386,432
Robert W. Doms · University Of Pennsylvania · U19 · FY2009 · AI

Allergen T cell epitopes and phenotypes during peanut immunotherapy

$386,424
Erik Wambre · Benaroya Research Inst At Virginia Mason · U19 · FY2019 · AI

Epigenetic Regulation of Plasma Cells Differentiation

$386,421
Jeremy M. Boss · Emory University · R01 · FY2020 · AI

Neoantigen-specific Adoptive T Cell Therapy for Glioblastoma, IND-BB-13135, protocol submitted 04/25/2020

$386,381
Gary W. Wood · Tvax Biomedical, Inc. · R01 · FY2022 · FD

Inter-metastatic divergency in small cell lung cancer; implications for the design of future immunotherapies

$386,376
Jose R Conejo-Garcia · Duke University · R01 · FY2025 · CA

In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices

$386,374
Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2021 · CA

In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices

$386,374
Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2020 · CA

In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices

$386,374
Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2022 · CA

RP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial Cancer

$386,325
David B. Solit · Sloan-Kettering Inst Can Research · P50 · FY2018 · CA